Malignant Mesothelioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: May 31, 2022 Report Code: GDGMDHC22181IDB-ST

Select Item

The Malignant Mesothelioma pipeline market report provides a comprehensive overview of the therapeutics under development for Malignant Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects.

Key Targets in the Malignant Mesothelioma Pipeline Drugs Market

In the Malignant Mesothelioma pipeline drugs market, the key targets are Cells Expressing Mesothelin, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD, DNA, Lymphocyte Activation Gene 3 Protein, Vascular Endothelial Growth Factor Receptor 2, and Wilms Tumor Protein. Cells Expressing Mesothelin has the highest number of pipeline products.

Malignant Mesothelioma Pipeline Drugs Market, by Targets

Malignant Mesothelioma Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Malignant Mesothelioma Pipeline Drugs Market

Cytotoxic To Cells Expressing Mesothelin has the highest number of pipeline products followed by Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, DNA Synthesis Inhibitor, Lymphocyte Activation Gene 3 Protein Inhibitor, Aminopeptidase N Inhibitor, and Cytotoxic To Cells Expressing Trophoblast Glycoprotein.

Malignant Mesothelioma Pipeline Drugs Market Analysis, by MoA

Malignant Mesothelioma Pipeline Drugs Market Analysis, by MoA

To get more insights on key MoA, download a free sample report

Malignant Mesothelioma Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Malignant Mesothelioma pipeline drug market are intravenous, oral, subcutaneous, intraperitoneal, intrapleural, intratumor, intravenous drip, intravesical, intradermal, parenteral, intralesional, and intramuscular. Intravenous has the maximum number of pipeline products.

Malignant Mesothelioma Pipeline Drugs Market Analysis, by RoA

Malignant Mesothelioma Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Malignant Mesothelioma Pipeline Drugs Market

The key molecule types in the Malignant Mesothelioma pipeline drugs market are small molecule, monoclonal antibody, gene-modified cell therapy, monoclonal antibody conjugated, fusion protein, subunit vaccine, cell therapy, recombinant protein, gene therapy, synthetic peptide, and oncolytic virus. Small molecule has the highest number of pipeline products.

Malignant Mesothelioma Pipeline Drugs Market, by Molecule Types

Malignant Mesothelioma Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free sample report

Major Companies in the Malignant Mesothelioma Pipeline Drugs Market

The major companies in the Malignant Mesothelioma pipeline drugs market are F. Hoffmann-La Roche Ltd, AstraZeneca Plc, Bayer AG, GlaxoSmithKline Plc, L.E.A.F. Pharmaceuticals LLC, Merck & Co Inc, Novartis AG, Bristol-Myers Squibb Co, Eli Lilly and Co, Ono Pharmaceutical Co Ltd, Pharma Mar SA, SELLAS Life Sciences Group Inc, and AGC Biologics SpA. F. Hoffmann-La Roche Ltd has the maximum number of pipeline products.

Malignant Mesothelioma Pipeline Drugs Market, by Major Companies

Malignant Mesothelioma Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Malignant Mesothelioma Pipeline Drugs Market Overview

Key Targets Cells Expressing Mesothelin, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD, DNA, Lymphocyte Activation Gene 3 Protein, Vascular Endothelial Growth Factor Receptor 2, and Wilms Tumor Protein
Key Mechanisms of action Cytotoxic To Cells Expressing Mesothelin, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, DNA Synthesis Inhibitor, Lymphocyte Activation Gene 3 Protein Inhibitor, Aminopeptidase N Inhibitor, and Cytotoxic To Cells Expressing Trophoblast Glycoprotein
Key Routes of Administration Intravenous, Oral, Subcutaneous, Intraperitoneal, Intrapleural, Intratumor, Intravenous Drip, Intravesical, Intradermal, Parenteral, Intralesional, and Intramuscular
Key Molecule Types Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Fusion Protein, Subunit Vaccine, Cell Therapy, Recombinant Protein, Gene Therapy, Synthetic Peptide, and Oncolytic Virus
Major Companies F. Hoffmann-La Roche Ltd, AstraZeneca Plc, Bayer AG, GlaxoSmithKline Plc, L.E.A.F. Pharmaceuticals LLC, Merck & Co Inc, Novartis AG, Bristol-Myers Squibb Co, Eli Lilly and Co, Ono Pharmaceutical Co Ltd, Pharma Mar SA, SELLAS Life Sciences Group Inc, and AGC Biologics SpA

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma
  • The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Mesothelioma therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Mesothelioma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Malignant Mesothelioma

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

A2 Biotherapeutics Inc
AbbVie Inc
ADC Therapeutics SA
ADCendo ApS
Adienne Pharma & Biotech SA
Advenchen Laboratories LLC
AGC Biologics SpA
Akeso Inc
Aldeyra Therapeutics Inc
Alligator Bioscience AB
Almac Discovery Ltd
Amgen Inc
Amphera BV
AnGes Inc
Apollomics Inc
Applied Research using OMIC Sciences SL
Arch Oncology Inc
Ares Immunotherapy Inc
Argenx SE
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Avenge Bio Inc
Bao Kang Biomedical Healthcare Inc
Bayer AG
Beijing Immunochina Pharmaceuticals Co Ltd
BerGenBio ASA
BioAtla Inc
Biocad
Biosion Inc
Biotheus Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calithera Biosciences Inc
CanBas Co Ltd
Cancure Ltd
Canget BioTekpharma LLC
Cedilla Therapeutics
Cellectis SA
Checkpoint Therapeutics Inc
Chiome Bioscience Inc
Clovis Oncology Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Delta-Fly Pharma Inc
Dyadic International Inc
Eisai Co Ltd
Eli Lilly and Co
Enlivex Therapeutics Ltd
Epigene Therapeutics Inc
EpimAb Biotherapeutics Inc
Epizyme Inc
Eureka Therapeutics Inc
F. Hoffmann-La Roche Ltd
FatiAbGen Corp
Fidia farmaceutici SpA
FKD Therapies Oy
Flag Therapeutics Inc
Genelux Corp
GlaxoSmithKline Plc
H2Biologics Inc
Harpoon Therapeutics Inc
Hebei Senlang Biotechnology Co Ltd
HiFiBiO Therapeutics Inc
Horizon Therapeutics Plc
Hutchison MediPharma Ltd
IDAC Theranostics Inc
Ikena Oncology Inc
ImmuNext Inc
ImmunityBio Inc
Immuno Cure BioTech Ltd
Immvira Co Ltd
Incyte Corp
Infinity Pharmaceuticals Inc
Inhibrx Inc
Innovent Biologics Inc
Inventiva SA
Invion Ltd
iOnctura SA
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
Kezar Life Sciences Inc
Kirilys Therapeutics Inc
Kiromic BioPharma Inc
Kyowa Kirin Co Ltd
L.E.A.F. Pharmaceuticals LLC
Laboratoires Pierre Fabre SA
Les Laboratoires Servier SAS
Lipac Oncology LLC
LipoSeuticals Inc
Luye Pharma Group Ltd
Marino Biotechnology Co Ltd
MELEMA Pharma GmbH
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Mina Therapeutics Ltd
Minneamrita Therapeutics LLC
Mirati Therapeutics Inc
Molecular Partners AG
Momotaro-Gene Inc
MorphoSys AG
Nanjing Bioheng Biotech Co Ltd
Nanjing CART Medical Technology Co Ltd
Navrogen Inc
NeoTX Therapeutics Ltd
NGM Biopharmaceuticals Inc
Novartis AG
Nurix Therapeutics Inc
Oasmia Pharmaceutical AB
Oncotelic Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
OSE Immunotherapeutics SA
Papyrus Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Pharmaxis Ltd
PlumeStars Srl
Polaris Pharmaceuticals Inc
Purmx Therapeutics Co Ltd
Quadriga BioSciences Inc
Rain Therapeutics Inc
RemeGen Co Ltd
RS Oncology LLC
Samjin Pharm Co Ltd
Sanofi
Seagen Inc
SELLAS Life Sciences Group Inc
Shanghai GeneChem Co Ltd
Shionogi & Co Ltd
SOTIO Biotech AS
SpringWorks Therapeutics Inc
Symphogen A/S
SynOx Therapeutics Ltd
Takeda Pharmaceutical Co Ltd
Tango Therapeutics Inc
Targovax ASA
TCR2 Therapeutics Inc
Tmunity Therapeutics Inc
TRACON Pharmaceuticals Inc
TREAT U SA
Ultimovacs AS
VasGene Therapeutics Inc
Venus Remedies Ltd
Verastem Inc
Verismo Therapeutics
ViroStatics SRL
Vivace Therapeutics Inc
VM Discovery Inc
Waterstone Hanxbio Pty Ltd
Xencor Inc
Y's Therapeutics Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Malignant Mesothelioma – Overview

Malignant Mesothelioma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Malignant Mesothelioma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Malignant Mesothelioma – Companies Involved in Therapeutics Development

Malignant Mesothelioma – Drug Profiles

Malignant Mesothelioma – Dormant Projects

Malignant Mesothelioma – Discontinued Products

Malignant Mesothelioma – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

  • What are the key targets in the Malignant Mesothelioma pipeline drug market?

    In the Malignant Mesothelioma pipeline drugs market the key targets are Cells Expressing Mesothelin, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD, DNA, Lymphocyte Activation Gene 3 Protein, Vascular Endothelial Growth Factor Receptor 2, and Wilms Tumor Protein.

  • What are the key mechanisms of action in the Malignant Mesothelioma pipeline drugs market?

    In the Malignant Mesothelioma pipeline drugs market the key mechanisms of action are Cytotoxic To Cells Expressing Mesothelin, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, DNA Synthesis Inhibitor, Lymphocyte Activation Gene 3 Protein Inhibitor, Aminopeptidase N Inhibitor, and Cytotoxic To Cells Expressing Trophoblast Glycoprotein.

  • What are the key routes of administration in the Malignant Mesothelioma pipeline drugs market?

    The key routes of administration in the Malignant Mesothelioma pipeline drug market are Intravenous, Oral, Subcutaneous, Intraperitoneal, Intrapleural, Intratumor, Intravenous Drip, Intravesical, Intradermal, Parenteral, Intralesional, and Intramuscular. Intravenous has the maximum number of pipeline products.

  • What are the key molecule types in the Malignant Mesothelioma pipeline drugs market?

    The key molecule types in the Malignant Mesothelioma pipeline drug market are Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Fusion Protein, Subunit Vaccine, Cell Therapy, Recombinant Protein, Gene Therapy, Synthetic Peptide, and Oncolytic Virus.

  • What are the major companies in the Malignant Mesothelioma pipeline drugs market?

    In the Malignant Mesothelioma pipeline drugs market the major companies are F. Hoffmann-La Roche Ltd, AstraZeneca Plc, Bayer AG, GlaxoSmithKline Plc, L.E.A.F. Pharmaceuticals LLC, Merck & Co Inc, Novartis AG, Bristol-Myers Squibb Co, Eli Lilly and Co, Ono Pharmaceutical Co Ltd, Pharma Mar SA, SELLAS Life Sciences Group Inc, and AGC Biologics SpA.

Malignant Mesothelioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Malignant Mesothelioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Malignant Mesothelioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more